Vertex Receives the US FDA’s IND Clearance of VX-264 for the Treatment of Type 1 Diabetes
Shots:
- The US FDA has cleared the IND to initiate a P-I/II clinical trial evaluating the safety, tolerability, and efficacy of VX-264 in ~17 patients with T1D. The study is expected to initiate in H1’23
- Vertex's VX-880 program has shown clinical PoC, and the P-I/II clinical study is still being conducted in the US and Canada. Additionally, VX-264 program does not require immunosuppression
- VX-880, is a stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy used in combination with immunosuppression. The clinical trial application (CTA) for VX-264 submitted by the company previously received approval from Health Canada
Ref: Businesswire | Image: Vertex
Related News:- Vertex Collaborated with Entrada Therapeutics to Develop Endosomal Escape Vehicle Therapies for Myotonic Dystrophy Type 1
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
